Evan Vista
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Evan Vista has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Babur Salim
Rheumatology Department Fauji Foundation Hospital Rawalpindi Pakistan
1 shared publication - Chak Sing Lau
Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
1 shared publication - Chin Teck Ng
Department of Rheumatology and Immunology Singapore General Hospital Singapore Singapore
1 shared publication - Chuanhui Xu
Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
1 shared publication - Debashish Danda
Department of Clinical Immunology and Rheumatology Christian Medical College Vellore India
1 shared publication - Galymzhan Togizbayev
Scientific Research Institute of Cardiology and Internal Diseases Almaty Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70752
2024 Update of the Asia‐Pacific League of Associations for Rheumatology ( APLAR ) Recommendations for Rheumatoid Arthritis Management
Aim: To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods: A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier studies where relevant. Recommendations were formulated based on this evidence and refined through a modified‐Delphi process during a series of online meetings. The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results: This update comprises 14 statements that achieved consensus during the meetings. Topics covered include measurement of disease activity and treatment response, the use of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), the use of targeted therapies, vaccination and screening for infections and the use of DMARDs during pregnancy. The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases. These recommendations are discussed in the context of the clinical landscape encountered in the Asia‐Pacific region. Conclusion: These updated recommendations complement previous APLAR guidelines and aim to support best practice management of RA across the Asia‐Pacific region. They provide a practical framework for national rheumatology associations to develop local guidelines adapted to their specific needs and clinical practice.
- 26 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70752
Open Access2024 Update of the Asia‐Pacific League of Associations for Rheumatology ( APLAR ) Recommendations for Rheumatoid Arthritis Management
Aim: To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods: A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier studies where relevant. Recommendations were formulated based on this evidence and refined through a modified‐Delphi process during a series of online meetings. The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results: This update comprises 14 statements that achieved consensus during the meetings. Topics covered include measurement of disease activity and treatment response, the use of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), the use of targeted therapies, vaccination and screening for infections and the use of DMARDs during pregnancy. The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases. These recommendations are discussed in the context of the clinical landscape encountered in the Asia‐Pacific region. Conclusion: These updated recommendations complement previous APLAR guidelines and aim to support best practice management of RA across the Asia‐Pacific region. They provide a practical framework for national rheumatology associations to develop local guidelines adapted to their specific needs and clinical practice.